TuHURA Biosciences (HURA) Expected to Release Earnings on Thursday

TuHURA Biosciences (NASDAQ:HURA) is projected to issue its Q2 2026 resultson Thursday, August 13th. Analysts expect the company to announce earnings of ($0.1533) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Friday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, analysts expect TuHURA Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TuHURA Biosciences Price Performance

Shares of TuHURA Biosciences stock opened at $2.09 on Thursday. The firm’s fifty day simple moving average is $2.27 and its 200-day simple moving average is $1.93. The stock has a market capitalization of $133.09 million, a price-to-earnings ratio of -3.43 and a beta of -0.01. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $3.90.

Institutional Trading of TuHURA Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in TuHURA Biosciences by 4.9% during the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after buying an additional 13,594 shares in the last quarter. Deutsche Bank AG increased its holdings in TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after buying an additional 54,051 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of TuHURA Biosciences by 6.4% during the 4th quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock worth $501,000 after acquiring an additional 39,710 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter worth approximately $79,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of TuHURA Biosciences in the 2nd quarter worth approximately $97,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 price objective on the stock. Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a report on Wednesday, April 15th. They issued a “buy” rating for the company. Citigroup initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics using high?dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first?in?class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.